Skip to content

10x Genomics, Inc. TXG Operating lease right-of-use asset amortization

Operating lease right-of-use asset amortization at other companies

Tempus AI, Inc. logo
Tempus AI, Inc.TEM
Repligen logo
RepligenRGEN
BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN

Other financials

Income statement

See full
Revenue$150.8M-2.6%
Gross profit$106.2M+0.7%
Operating income-$17.0M+56.7%
Net income-$13.5M+60.8%
EPS (diluted)-$0.10+64.3%

Balance sheet

See full
Cash & equivalents$490.3M+30.0%
Total debt$81.4M+1.6%
Total equity$814.3M+15.2%
Total assets$1.0B+12.4%

Cash flow

See full
Operating cash flow$26.1M-24.0%
CapEx$1.6M-15.6%
Free cash flow$24.5M-24.4%

Valuation

See full
Market cap$4.41B+154%

Profitability

See full
Gross margin69.6%+1.2pp
Operating margin-6.1%-2.7pp
Net margin-3.5%-1.6pp
FCF margin19.1%

Returns & leverage

See full
Return on equity-3%-1.4pp
Debt / equity0.1×0.0×
Current ratio5.9×+0.5×

Where this comes from

Reported directly by 10x Genomics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about 10x Genomics, Inc.'s operating lease right-of-use asset amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is 10x Genomics, Inc.'s operating lease right-of-use asset amortization?
10x Genomics, Inc. (TXG) reported operating lease right-of-use asset amortization of $1.95M in Q1 2026.